Bayesian Capital Management LP Invests $193,000 in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Bayesian Capital Management LP purchased a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 25,700 shares of the biotechnology company's stock, valued at approximately $193,000.

A number of other large investors have also bought and sold shares of BCRX. Xponance Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 9.1% in the fourth quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company's stock valued at $112,000 after buying an additional 1,242 shares in the last quarter. Sei Investments Co. raised its holdings in shares of BioCryst Pharmaceuticals by 2.8% in the 4th quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company's stock worth $430,000 after acquiring an additional 1,537 shares during the last quarter. Mariner LLC lifted its position in BioCryst Pharmaceuticals by 32.1% in the 4th quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock valued at $100,000 after acquiring an additional 3,224 shares in the last quarter. Arizona State Retirement System boosted its stake in BioCryst Pharmaceuticals by 6.6% during the 4th quarter. Arizona State Retirement System now owns 57,001 shares of the biotechnology company's stock valued at $429,000 after purchasing an additional 3,518 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in BioCryst Pharmaceuticals by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 43,920 shares of the biotechnology company's stock worth $330,000 after purchasing an additional 4,129 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on BCRX shares. StockNews.com upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Tuesday, May 6th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Wedbush began coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 target price for the company. Evercore ISI boosted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. Finally, Barclays increased their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $16.56.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX traded up $0.06 during trading hours on Friday, reaching $9.98. The stock had a trading volume of 7,606,302 shares, compared to its average volume of 2,989,382. BioCryst Pharmaceuticals, Inc. has a 12-month low of $5.34 and a 12-month high of $11.11. The stock has a 50 day simple moving average of $7.87 and a 200 day simple moving average of $7.89. The stock has a market cap of $2.09 billion, a P/E ratio of -16.36 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. The firm's revenue for the quarter was up 40.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.28 earnings per share. On average, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.